These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Biodiversity of small molecules--a new perspective in screening set selection. Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345 [TBL] [Abstract][Full Text] [Related]
5. Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification. Beresini MH; Liu Y; Dawes TD; Clark KR; Orren L; Schmidt S; Turincio R; Jones SW; Rodriguez RA; Thana P; Hascall D; Gross DP; Skelton NJ J Biomol Screen; 2014 Jun; 19(5):758-70. PubMed ID: 24518067 [TBL] [Abstract][Full Text] [Related]
6. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667 [TBL] [Abstract][Full Text] [Related]
8. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858 [TBL] [Abstract][Full Text] [Related]
9. Optimal HTS Fingerprint Definitions by Using a Desirability Function and a Genetic Algorithm. Cortes Cabrera A; Petrone PM J Chem Inf Model; 2018 Mar; 58(3):641-646. PubMed ID: 29425455 [TBL] [Abstract][Full Text] [Related]
10. Increasing the delivery of next generation therapeutics from high throughput screening libraries. Wigglesworth MJ; Murray DC; Blackett CJ; Kossenjans M; Nissink JW Curr Opin Chem Biol; 2015 Jun; 26():104-10. PubMed ID: 25909818 [TBL] [Abstract][Full Text] [Related]
11. The European Lead Factory: An updated HTS compound library for innovative drug discovery. van Vlijmen H; Ortholand JY; Li VM; de Vlieger JSB Drug Discov Today; 2021 Oct; 26(10):2406-2413. PubMed ID: 33892142 [TBL] [Abstract][Full Text] [Related]
12. Open access high throughput drug discovery in the public domain: a Mount Everest in the making. Roy A; McDonald PR; Sittampalam S; Chaguturu R Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896 [TBL] [Abstract][Full Text] [Related]
13. Cheminformatics approaches to analyze diversity in compound screening libraries. Akella LB; DeCaprio D Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001 [TBL] [Abstract][Full Text] [Related]
14. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space. Koutsoukas A; Paricharak S; Galloway WR; Spring DR; Ijzerman AP; Glen RC; Marcus D; Bender A J Chem Inf Model; 2014 Jan; 54(1):230-42. PubMed ID: 24289493 [TBL] [Abstract][Full Text] [Related]
15. Stratified high-throughput screening sets enable flexible screening strategies from a single plated collection. Nissink JW; Schmitt S; Blackburn S; Peters S J Biomol Screen; 2014 Mar; 19(3):369-78. PubMed ID: 23918919 [TBL] [Abstract][Full Text] [Related]
16. Case studies of minimizing nonspecific inhibitors in HTS campaigns that use assay-ready plates. Liu Y; Beresini MH; Johnson A; Mintzer R; Shah K; Clark K; Schmidt S; Lewis C; Liimatta M; Elliott LO; Gustafson A; Heise CE J Biomol Screen; 2012 Feb; 17(2):225-36. PubMed ID: 21940710 [TBL] [Abstract][Full Text] [Related]
18. Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy. Bakken GA; Bell AS; Boehm M; Everett JR; Gonzales R; Hepworth D; Klug-McLeod JL; Lanfear J; Loesel J; Mathias J; Wood TP J Chem Inf Model; 2012 Nov; 52(11):2937-49. PubMed ID: 23062111 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Iterative Screening with Stepwise Compound Selection Based on Novartis In-house HTS Data. Paricharak S; IJzerman AP; Bender A; Nigsch F ACS Chem Biol; 2016 May; 11(5):1255-64. PubMed ID: 26878899 [TBL] [Abstract][Full Text] [Related]
20. Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening. Honarnejad S; van Boeckel S; van den Hurk H; van Helden S SLAS Discov; 2021 Feb; 26(2):192-204. PubMed ID: 32734803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]